ModernaMRNA
MRNA
About: Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Employees: 5,800
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
29% more repeat investments, than reductions
Existing positions increased: 255 | Existing positions reduced: 197
0.37% more ownership
Funds ownership: 71.87% [Q4 2024] → 72.24% (+0.37%) [Q1 2025]
8% less funds holding
Funds holding: 729 [Q4 2024] → 673 (-56) [Q1 2025]
13% less funds holding in top 10
Funds holding in top 10: 8 [Q4 2024] → 7 (-1) [Q1 2025]
22% less call options, than puts
Call options by funds: $800M | Put options by funds: $1.03B
31% less capital invested
Capital invested by funds: $11.5B [Q4 2024] → $7.9B (-$3.6B) [Q1 2025]
32% less first-time investments, than exits
New positions opened: 87 | Existing positions closed: 128
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$26
3%
downside
Avg. target
$38
42%
upside
High target
$70
162%
upside
6 analyst ratings
1 positive
17%
4 neutral
67%
1 negative
17%
JP Morgan Jessica Fye | 3%downside $26 | Underweight Maintained | 22 May 2025 |
UBS Eliana Merle | 162%upside $70 | Buy Maintained | 2 May 2025 |
Barclays Gena Wang | 50%upside $40 | Equal-Weight Maintained | 2 May 2025 |
RBC Capital Luca Issi | 5%upside $28 | Sector Perform Maintained | 2 May 2025 |
Evercore ISI Group Cory Kasimov | 20%upside $32 | In-Line Maintained | 2 May 2025 |
Financial journalist opinion
Based on 50 articles about MRNA published over the past 30 days
Negative
Zacks Investment Research
1 day ago
Here's Why Moderna (MRNA) Fell More Than Broader Market
Moderna (MRNA) closed the most recent trading day at $26.68, moving 2.45% from the previous trading session.
Negative
Reuters
1 day ago
Moderna falls on fears new CDC vaccine advisory panel could cloud RSV shot prospects
Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the company's respiratory syncytial virus vaccine in a broader age group.
Positive
Reuters
2 days ago
US FDA approves expanded use of Moderna's RSV vaccine for at-risk adults
The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a lower group of high-risk adults aged 18 to 59 years.
Neutral
Accesswire
2 days ago
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA® (mRNA-1345), the Company's respiratory syncytial virus (RSV) vaccine, for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18-59 years of age who are at increased risk for disease. This approval expands the previous indication of mRESVIA, which was approved in May 2024 for adults aged 60 years and older.
Negative
The Motley Fool
2 days ago
Is it Time to Dump Your Shares of Moderna?
After soaring to success in the early days of the COVID-19 pandemic, Moderna (MRNA 0.25%) experienced a reversal of fortune. The coronavirus vaccine maker has seen revenue plummet as demand for this flagship product -- Moderna's first to be approved -- has slipped.
Neutral
Seeking Alpha
2 days ago
Moderna, Inc. (MRNA) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Moderna, Inc. (NASDAQ:MRNA ) Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 8:40 AM ET Company Participants Stéphane Bancel - CEO & Director Conference Call Participants Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division Salveen Jaswal Richter Great. Good morning, everyone.
Neutral
Accesswire
3 days ago
Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025
CAMBRIDGE, MA / ACCESS Newswire / June 11, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor event: Barclays Speaking the Science Call Series, on Monday, June 16th at 10:00am ET A live webcast of this presentation will be available under "Events and Presentations" in the Investors section of the Moderna website. investors.modernatx.com.
Negative
Market Watch
3 days ago
20 stocks you should avoid — no matter how well the market does
These hard-to-short stocks are likely to lose money, researchers found.
Negative
CNBC
4 days ago
RFK Jr.'s firing of CDC vaccine advisors 'circumvents science' and could threaten public health, experts say
Health and Human Services Secretary Robert F. Kennedy Jr. has gutted a key government panel of vaccine advisors, a stunning move that some public health experts say undermines science, disrupts a trusted regulatory process and could sow public distrust in vaccinations and federal health agencies.
Negative
Reuters
4 days ago
Vaccine actions and policy positions under US Health Secretary Kennedy
U.S. Health Secretary Robert F. Kennedy Jr., a long-time vaccine skeptic, has been making sweeping changes to reshape U.S. regulation of vaccines, food and medicine.
Charts implemented using Lightweight Charts™